Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLK-33
- Development stage
- Preclinical
- Lead developer
- Glykos
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GLK-33 is a novel antibody-drug conjugate (ADC) developed by Gliknik for the treatment of CD33-positive acute myeloid leukemia (AML). It consists of the humanized anti-CD33 monoclonal antibody lintuzumab conjugated to approximately eight mavg-MMAU (monomethyl auristatin U) linker-payloads. GLK-33 is designed to address the limitations of earlier CD33-targeted ADCs, such as gemtuzumab ozogamicin, by offering a wider therapeutic window and improved tolerability. Preclinical studies have demonstrated that GLK-33 exhibits potent antitumor activity against CD33-positive leukemia cell lines, primary AML samples, and multidrug-resistant cells, while maintaining a favorable safety profile in animal toxicology models.
- Other names
- lintuzumab-mavg-MMAU
02
Targets
CD33 (Myeloid cell surface antigen CD33)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on GLK-33.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLK-33.